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Abstract 
Oxygen-ozone therapy has been piloted in Italy patients with
ischemic heart disease or suffering from myocardial infarction
since 1991. Over time, it has been observed that ozone exerts a
significant anti-inflammatory and rheological activity: ozone acti-
vates the redox system, lowers the pro-inflammatory
cytokines16β, TNFα, modulates the NF-KB system, reduces
platelet aggregation, and stimulates the release of growth factors.
It is because of these characteristics that oxygen-ozone therapy is
used in the prevention and treatment of ischemic heart disease and
for post-infarction rehabilitation. The case study – a critically ill
patient aged 76 with acute myocardial infarction (AMI), suffering
from ischemic heart disease and heart attacks, high blood pres-
sure, renal failure, ischemic vascular pluri-infarct CNS disease,
Parkinsonism, stroke, neurological bladder disease and debilitat-
ing inguinal hernia – after a year and a half of AMI with infusions
of autologous blood treated with ozone (GAE), recovered the left
ventricular ejection fraction from 33 to 50% and underwent a suc-
cessful inguinal hernia operation. It appears evident that oxygen
ozone therapy using GAE protect the hearts of patients suffering
from ischemic heart disease, and is useful during the acute phase
of infarctions, as well as for rehabilitating patients who have had
an AMI with stenting.
Introduction
Oxygen ozone therapy in patients with ischemic heart disease
or had suffered acute myocardial infarction (AMI), was first tested
in Italy at the end of 1991, when Prof. B. Lettieri, Professor of
Anaesthesia and Reanimation at the Federico II of Naples treated
several patients with ozonised autologous blood infusions during
the acute phase of myocardial infarction1 and obtained favourable
results in terms of pain and prognosis. In 1996, oxygen-ozone
therapy was used in the prevention of recurrent AMI, and signifi-
cant protection from re-infarction was demonstrated.2
Ozone exerts an important anti-inflammatory and rheological
activity, despite being a strong oxidant, via its paradoxical effect
of activating the cellular antioxidant system,3 which modulates the
functioning of endogenous cellular enzymes that protect cells
against free radicals, and increases DNA transcription at the level
of antioxidant enzymes. It activates the Redox system, lowering
the pro-inflammatory cytokines 1β, 6 TNFα,4 modulates the NF-
KB system,5 reduces platelet aggregation6 and stimulates the
release of various growth factors.6,7
Due to these characteristics, oxygen-ozone therapy was used for
the prevention and treatment of ischemic heart disease and in post-
infarct rehabilitation. The ejection fraction of the left ventricle
remained under 33% from January 2014 to March 2015, despite
coronary angioplasty and medical treatment. After a year and a half
of AMI, the patient started the oxygen-ozone therapy using GAE, he
recovered the left ventricular ejection fraction, from 33 to 50%, and
successfully underwent inguinal hernia surgery.
Case Report
The case report examines the outcome of treatment with oxy-
gen-ozone therapy in a 76-year-old critically ill patient, with a pre-
vious myocardial infarction, suffering from ischemic heart disease
and myocardial infarction (January 2014), high blood pressure,
kidney disease, parkinsonism, ischemic cerebrovascular pluri-
infarcts, brain ictus, a neurological bladder and a debilitating
inguinal hernia. The ejection fraction of the left ventricle was
assessed by repeated echocardiographic examinations, and
remained under 33% from January 2014 to March 2015, despite
coronary angioplasty and medical treatment. 
From 3 July 2015, the patient was subjected to an oxygen
ozone therapy cycle via 2 autologous infusions of ozonized blood
Correspondence: Sergio Pandolfi, Scientific Society of Oxygen-Ozone
Therapy, via Roma 69, Gorle (BG), Italy.
Tel/Fax: +39.035.300903.
E-mail: sergiopandolfis2@gmail.com
Key words: Oxygen ozone therapy; Cardiac function; Myocardial
infarction; Autologous blood treated with ozone (GAE).
Received for publication: 12 April 2017.
Accepted for publication: 19 April 2017.
©Copyright S. Pandolfi et al., 2017
Licensee PAGEPress, Italy
Ozone Therapy 2017; 2:6745
doi:10.4081/ozone.2017.6745
This article is distributed under the terms of the Creative Commons
Attribution Noncommercial License (by-nc 4.0) which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
Effects of oxygen ozone therapy on cardiac function in a patient with aprior myocardial infarction
Sergio Pandolfi,1,2 Angelo Zammitti,1,2 Marianno Franzini,1,3 Vincenzo Simonetti,1,4 William Liboni,5
Luigi Valdenassi,1,3 Filippo Molinari6
1Scientific Society of Oxygen-Ozone Therapy, Gorle (BG); 2Villa Mafalda Nursing Home, Rome; 3Department of
Internal Medicine and Medical Therapy, Master in Oxygen-Ozone Therapy, University of Pavia; 4Kaos non-profit
Association, Caselle Torinese (TO); 5Un Passo Insieme Onlus Foundation, Valdellatorre (TO); 6Department of
Electronics and Telecommunications, Politecnico di Torino, Turin, Italy
No
n-c
om
me
rci
al 
us
e o
nly
(GAE) on a weekly basis. During the first two months of therapy,
the patient showed a marked improvement in cardiac status with a
reduction in asthenia and improvement in neurological status. The
improved cardiac status was confirmed by an echocardiogram on
05/11/2015, which showed an increase in the left ventricular ejec-
tion fraction of 33-50%. In this case, the improvements in cardiac
function and left ventricular EF were detected only after starting
systemic oxygen ozone therapy using GAE. In April 2015, before
starting the oxygenated ozone therapy, the inguinal hernia had
been assessed as inoperable in view of the low cardiac status, while
at the next reassessment in December 2015, after having been sub-
jected to oxygen ozone therapy for five months, it was judged
operable due to improvements in cardiac function. On February
19, 2016 the inguinal hernia was successfully operated on.
Administration of oxygen-ozone was performed via GAE, using
bags approved for oxygen ozone therapy, in accordance with EC
regulations. 
The ozone generator used was a Multiossigen Medical 95,
EEC 93/42 certified in class2a. For each procedure 200-220 mL of
blood were collected, and treated with 200 cc of a mixture of ozone
in oxygen at a concentration of 40 micrograms of ozone. 
Discussion
Ozone is a gas characterised by its instability, which is natural-
ly present in the body and the atmosphere. Its administration into
an organism leads to an initial, transient oxidative stress that the
redox systems of the blood and plasma work together to counter-
act. Obviously the concentrations of ozone used therapeutically
never exceed the antioxidant potential of the blood.8-10
When placed in contact with the plasma, ozone reacts instantly
with the antioxidant systems (especially uric acid, ascorbic acid,
glutathione, cysteine and albumin), therefore, only a small part of
the initial dose reacts with polyunsaturated fatty acids (PUFAs). 
Therefore, the potential energy of the ozone is transferred to two
main messengers, such as H2OR2 and the aldehyde molecules 4-
hydroxynonenal (4HNE) and trans-4-hydroxyhexenal (HHE). Given
the high reactivity of ozone, these reactions take place within a few
seconds, and a few minutes of contact between blood and the mix-
ture of oxygen-ozone is generally sufficient, because ozone is com-
pletely exhausted and the oxygen saturates the haemoglobin system,
dissolving into the plasma. The antioxidant systems are mainly
replenished within 20 minutes of exposure to the gas mixture.
De-ionised H2OR2 quickly enters all of the blood cells and
induces the following changes: in active erythrocytes, glycolysis,
increasing intracellular concentrations of ATP and 2, 3 DPG. This
translates into a right shift of the haemoglobin dissociation curve,
which therefore more readily releases oxygen into the peripheral
tissues.10 In leukocytes, the phagocytic activity of neutrophils is
increased. In lymphocytes and macrophages, intracellular LKB
patterns, one of the components of NFkB are activated. The trimer,
which is degraded in proteasomes into the hetero-dimers p50-p65,
can activate the transcription of over 100 genes. Interleukins are
produced, as are various acute phase proteins, as well as IFN and
TNFα.11 In platelets, PDGF AB, TGFB1 and growth factors are
produced. 
The aldehydes react with GSH, carnosine and albumin in par-
ticular, and are transported into various body tissues. The toxicity
of 4HNE and HHE is contrasted by compensatory mechanisms
like detoxification, dilution and excretion; these compounds, in
fact, recognized as oxidizing agents, induce a response from the
body that produces SOD, haem-oxygenase, G6PDH and other
powerful antioxidants. The aldehydes also stimulate the production
of endothelial Nos,12 improving peripheral perfusion and tissue
oxygenation. In addition, in a randomised clinical study of 140
patients, of which 70 were subjected to oxygen ozone therapy and
70 were a control group, blood chemistry parameters showed a
decrease in Reactive Oxygen Metabolites (300±10.1 UCARR at 12
months compared to an initial value of 380±10.4 UCARR, P<0.05)
and an increase in plasma Biological Antioxidant potential values
(2100±34.8 micromoles/vitamin C after 12 months compared to an
initial value of 1610±36.2, P<0.05) in treated patients compared to
the control group.13
These data demonstrate that ozonized blood haemoinfusions
play a role in reducing oxidative stress by endogenously stimulat-
ing the production of antioxidant enzymes.
After input from Prof. Lettieri in 19911 and 19962 several studies
on mice were conducted: when subjected to myocardial ischemia,
rats pre-treated with oxygen ozone therapy showed smaller ischemic
areas and improved cardiac function indexes than those that were not
treated with ozone.12-14 As for in vivo studies, in 2008 the
ACCLAIM trial was published;15 this was a randomised double-
blind study in which NYHA II-IV patients were given ozonized
blood using the Celacade System, which provides small amounts of
blood (10-20 ml) that have been exposed to large concentrations of
ozone, which is then processed and heated at 42°C under UV light,
and then re-injected into the buttock, and is comparable to a small
auto haemoinfusions of ozonised blood. The study showed a corre-
lation between administering this treatment, oxygen ozone therapy,
which is described as non-specific immuno-modulatory, and clinical-
ly assessed events like death from any cause, hospitalisation for car-
diac reasons, the need for i.v. therapy for heart failure etc. The
results, however, favoured treatment with ozone, despite an incom-
plete therapeutic procedure being performed and not having per-
formed GAE (large auto haemotherapy) that are indicated in all dis-
eases of the organs, microcirculation and ischemias. The scientific
community16 has questioned using a method like Celacade for ozone
therapy, since the high concentration, when used on a small blood
samples, exceeds the redox potential of the plasma, whilst the heat
and UV rays it uses denature most of corpuscular components.16,17
In another study, the effects of acute administration of a mix-
ture of oxygen/ozone (O3) were assessed in damaged myocardial
tissue following an ischemic event.18 The study was performed on
rats subjected to acute myocardial ischaemia and reperfusion. The
animals were treated with an oxygen-ozone mixture of 100, 150
and 300 micrograms/kg injected intraperitoneally one hour before
the ischemic damage.
Infarct size, markers of necrosis and tissue damage, nitro tyro-
sine, CD68, CD8, CD4 and caspase-3 levels were measured. The
results showed a smaller sized area infarction in rats pre-treated by
insufflation with the oxygen-ozone mixture, and a parallel reduc-
tion in tissue levels of nitro tyrosine, inflammatory markers
(CD68) and of the immune response (CD8 and CD4). These data
indicated that the damage associated with ischemia and myocardial
reperfusion could be counteracted by pre-treatment with systemat-
ically administered gaseous mixtures of oxygen-ozone.
Other more recent studies have shown that after a myocardial
infarction, the level of endothelial progenitor cells in the myocardi-
um is reduced. These cells are derived from bone marrow, and
serve to mobilise, migrate and differentiate into endothelial cells in
situ, forming a mobile cellular reserve that can repair endothelial
damage. Strategies to increase the CEP in an ischemic heart seem
to improve the neo vascularisation of ischemic tissue, and may
improve myocardial blood flow by decreasing ischemic damage.
One experimental study in animals18 showed that oxygen/ozone
treatment protected the heart from AMIs thanks to a localised
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increase in eNOS activity, and the recruitment of endothelial pro-
genitor cells.
The ability of oxygen ozone therapy to lower re-stenosis rates
after implanting metal stents in pigs due to its antioxidant and anti-
inflammatory properties has recently been assessed.19 The recur-
rence of the stenosis, re-stenosis, or the lack of re-endothelialisa-
tion can occur after percutaneous trans-luminal coronary angio-
plasty, even when medicated drug-eluting stents are used, due to
inflammation and oxidative stress at an endothelial level. Twelve
male Landrace pigs (51±9 kg) were subjected to percutaneous
transluminal metal stenting in the circumflex coronary arteries
under infusion of heparin with fluoroscopic guidance using stan-
dard techniques. This randomised study was conducted with 6 pigs
subjected to ozone-oxygen therapy and the other 6 pigs receiving
a placebo treatment. Before applying the stent (24 hours before)
and twice a week for 30 days after stenting, venous blood was col-
lected, ozonized and reinfused. The same procedure was per-
formed in the placebo group, with the ozone treatment omitted.
Both groups received an anticoagulant treatment. Histopathology
and immunohistochemical assessments were performed. The
results of the study showed a severe inflammatory reaction and re-
stenosis, with an increase in the immunohistochemical expression
of thioredoxin-1 in the placebo group, 30 days after the surgery.
Contrarily, ozone therapy significantly reduced the inflammatory
response and re-stenosis, and no immunohistochemical increase in
Trx-1 expression was evident 30 days after surgery. The same
immune marker for PRX-2 was negative in both groups.
Surprisingly, ozonised autologous haemotherapy reduced re-steno-
sis 30 days after PTCA with BMS implantation in pigs.
Stimulation of the redox system, superoxide dismutase, catalase,
carnosine, albumins, haem-oxygenase and G6PDH due to the pre-
treatment with ozone neutralised the oxidative damage by increas-
ing the post-ischemic antioxidant capacity, which reduced the
damage, the need for antioxidant enzymes and the risk of re-steno-
sis with the stent. 
It is interesting to note that data reported by Profs. Lettieri and
Chiefari at the University of Naples1,2 also showed that essentially,
the possibility of recovering myocardial tissue affected by infarc-
tion depended on the treatment used, in both the early hours of pain
and in the phase of coronary reperfusion, because, at these times,
the highest mortality rates are observed. The use of thrombolytics
can reduce the necrotic area, but there is some evidence it can easy
induce the onset of severe rhythmic disorders, immediately after
the restoration of myocardial re-vascularisation in the territory
affected by ischemia, due to toxic substances like oxygen free rad-
icals, leukotrienes and bradykinins being formed and entering the
circulation. The group of patients treated with oxygen-ozone ther-
apy via large ozonised autologous haemotherapy showed a faster
disappearance of pain; furthermore, the extent of the infarcted area
in them was more limited, because it lowered the viscosity of the
blood and improved its rheology (the flow of blood through the
vessels). This allowed a significant increase in perfusion of the
area surrounding the infarct at an early stage of the condition, thus
achieving, via the capillaries, low blood viscosity and the recovery
of perfusion in the at risk zone.
In this study,1 conducted by Prof. Lettieri et al., acute phase
AMI patients were treated with oxygen-ozone therapy mediated
through large auto haemoinfusions of ozonised blood. Two groups
of infarcted patients were selected: 1) the first group was subjected
to conventional treatment (group A); 2) the second group (group
B), in addition to conventional treatment, was subjected to oxygen-
ozone-therapy, according to the following scheme: 150 cc of blood
were taken, mixed with oxygen-ozone and re-infused. The first
treatment was administered within 20 minutes of admission to hos-
pital, the second 48 hours afterwards and the third at 96 hours.
Assessments regarding the extent of reperfusion were based on the
occurrence, in relation to times, of the following events: 1) the dis-
appearance or significant reduction of chest pain; 2) the reduction
of the increased ECG ST-segment and; 3) the rapid release of
serum CK-MB, with an early peak. Cardiac perfusion assessments
are made on the basis of echocardiogram results, the possibility of
myocardial tissue recovery, onset of an acute ischemic event, and
are greatly influenced by behaviour therapy, used both in the first
painful hours and at the coronary reperfusion stage. These are the
most sensitive times in intensive treatment of these patients. This
statement is supported by the international literature, which shows
the highest death rates occur during in these two stages. The con-
clusions of large trials performed the 80s opened a window of
opportunity for reducing the necrotic area caused by an acute
thrombotic process in one or more coronary branches, through the
early use of thrombolytic agents, but, unfortunately, also highlight-
ed how easy it is for severe rhythmic disorders to set in, immedi-
ately after restoring vascularisation to the myocardial territory
affected by ischemia, due to the formation of toxic substances like
oxygen free radicals, leukotrienes and bradykinins that enter the
circulation. It has also been noted that the tissues surrounding the
necrotic area, in the earliest hours following an infarct, are
involved in a process of intense perifocal oedema, with onsite
accumulation of K+ and catecholamines: this phenomenon causes
a typical action potential, described by Cranfield (Mount Kisko
Hospital, NY, USA) as a slow response; in the area surrounding the
focus, which is prone to oedema, and, more peripherally, to reac-
tive ischemia, the impulse is, so to speak, sequestered in a portion
of the conduction system, which allows normal perfusion to the
surrounding tissues to unleash ectopic rhythms, peri-lesional elec-
trical instabilities.
Weighing up the advantages and limitations of thrombolytic
treatment in an attempt to achieve the dual objectives of reducing
infarct size as it develops, and, at the same time, avoiding the
establishment of dangerous arrhythmias as far as possible, Prof.
Lettieri decided to render an original infarct treatment for infarc-
tion in the acute phase, by mixing ozone with a quantity of
patient’s blood and subsequently reinfusing it into the circulation
at a very early stage, relative to the time the pain started. For this
purpose, two homogeneous groups of patients were selected, both
suffering from myocardial infarction, both observed within 8 hours
of the painful symptomatology arising, and aged between 42 and
64 years. The first group was subjected to traditional therapy; the
second to oxygen-ozone therapy, administered by auto haemo infu-
sions  of ozonised blood, before informed consent and clinical and
instrumental diagnosis of the myocardial infarction.
In addition to conventional treatment the second group, desig-
nated B, was subjected to ozonisation therapy, using following
scheme: 150 cc of blood were taken and mixed with ozone-oxy-
gen, then the blood was re-infused into a vein, at a slow drip rate.
The first treatment was carried out within 20 minutes of admission;
the second 48 hours afterwards; the third at 96 hours. The infusion
therapy was initiated depending on the individual needs of the
patients, regardless of the double-blinding. Judgments about the
extent of reperfusion were based on the occurrence, in terms of
time relationships, of the following events: 1) the disappearance,
or a significant reduction in chest pain; 2) the extent of to which
the S-T segment elevation dropped, with a progressive trend
towards the isoelectric line, or with values equal to or less than
50% of the baseline value; 3) how fast serum CKMB was released
with an early peak (greater than or equal to 16 h); if the infarction
index enzymes stabilised within 16 hours it indicated there has
been a good re-perfusion. 
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A cardiac performance score was awarded, on the basis of the
results of a two-dimensional echocardiogram. The global kinetic
and ejection fraction were evaluated using the Simpson method.
The kinetic segmental, which is an entirely subjective observa-
tion, was quantified using a score of 3=normokinesia to -1=dysk-
inesia.
On comparing the two groups of patients with regard to pain,
which is a sign of myocardial ischemia, the results showed that
average values (at 24 hours from pain onset) for group A were 5.5
points, corresponding to moderate to severe pain; whilst in group
B, the score was 3, corresponding to mild pain. At 36-hours post-
admission, the scores for both groups showed no significant varia-
tions, settling down to a score of 2 (just appreciable value).
Significant results did emerge in CK-MB kinetics. In group A, the
peak on the enzymatic curve was observed to extend beyond 19
hours of pain in 20% of cases, whilst in group B, the percentage
was 10 (a value assessed as persistent occlusion.) 
An earlier fall in CK blood levels was observed, before 16
hours (having been re-perfused), in 60% of patients in group B,
treated with oxygen-ozone therapy, compared to 40% of group A.
From these data, we can deduce that the extent of the infarction
was more limited in the group treated with oxygen-ozone, com-
pared to the group treated with traditional therapy. Comparing now
the sum of the electrocardiographic derivations present in the ST
segment before treatment using the methods already described,
with the sum of derivations, which showed a Q wave of necrosis,
three weeks after infarction, a relationship was observed in favour
of group B. Yet the fibrinogen rate, from the time of hospitalisation
until the seventh day, after three cycles of treatment with oxygen-
ozone, was observed to decrease by 43.7% in group B compared to
baseline, whilst in group A, a decrease of 18% was observed.
Bearing in mind that mechanical events occur earlier than electri-
cal events, echocardiographic monitoring was carried out using the
calculated ejection fraction obtained from the relationship between
cardiac output and end-diastolic volume; in the first day, almost
overlapping values were observed in the two groups, until, on the
twentieth day, a five-point difference between the two groups was
attained, in addition to which, in the last echocardiogram for group
B, the ejection fraction value in toto approached normal. The
encouraging findings emerging from this study confirmed the
validity of autologous ozonised blood infusions in ischemic heart
disease.
The clinical and instrumental results were evaluated, the bene-
ficial rheological effect of oxygen-ozone-therapy, which result in a
significant reduction of blood viscosity, both as regard to the defor-
mation of corpuscular component of the red blood cell series, as
well as of those referred to as coagulation factors. Various authors
have, over the years, reported ozone causes structural changes to
fatty acids, which are basic constituents of biological membranes,
that increase the plasticity of red blood cells; and yet, this gas cre-
ates a barrier of negative electric charges. This double action
would respectively allow greater diffusibility of blood and an
improvement in the microcirculation.
At an early stage of the disease this phenomenon would allow
a significant increase in perfusion of the area surrounding the
necrotised zone: the zone which is, in the acute phase of myocar-
dial infarction, facing a dual destiny: firstly the danger that reactive
vasoconstriction and the presence of toxic substances released
from the necrotising area will accentuate the ischaemia until it
widens the infarct, with an aggravation of the prognosis quoad
vitam; or, secondly, where, via preferential microcirculation chan-
nels, it is possible to attain blood of a lower viscosity and induce
recovery of blood perfusion in the risk zone; both of which are phe-
nomena that appear to occur during treatment with oxygen-ozone
therapy. Finally, it may be advisable to check, by follow-up at a
distance with a greater number of patients treated with ozone, the
significance of the drop in blood fibrinogen and the prolongation
of coagulation parameter times.
As regards the improvements in rheology attributed to the fib-
rinogen decrease in patients undergoing GAE, a preliminary study
into the efficacy of oxygen-ozone therapy for preventing recurrent
myocardial infarction by exploiting the rheological effect of ozone,
showed that patients with a previous myocardial who were subject-
ed to GAE had a reduced risk of AMI recurrence.
Conclusions 
The clinical history of this patient, who, at 74 years of age
(January 2014), suffered a myocardial infarction with parkinson-
ism, hypertension, chronic renal disease and dyslipidaemia as co-
morbidities, and received oxygen-ozone therapy using large autol-
ogous ozonized blood infusions (GAE) for 18 months, demon-
strates that this method acts on the heart’s functional recovery by
improving myocardial contractility and protects against the risk of
subsequent recurrences of AMI. The 76-year-old patient who was
the subject of this work is currently in maintenance therapy receiv-
ing one GAE per week, using 200-220 g of blood exposed to a
mixture of oxygen and ozone at concentrations of 40-50 µg of O3,
and has shown an improvement in general condition, mood recov-
ery, stabilisation of cardiac function and normalisation of renal
parameters, with further improvement in ambulation after a volu-
minous inguinal hernia was removed, and stable Parkinson’s.
Clearly, oxygen ozone therapy using GAE protects the heart of
patients suffering from ischemic heart disease, and is useful in the
acute phase of infarctions, and for rehabilitating patients who have
had an AMI with stenting.
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